1. Volume 16, Issue 8, Pages 967-978 (August 2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial 
Prof Juan W Valle, MD, Harpreet Wasan, MD, Andre Lopes, MSc, Alison C Backen, PhD, Prof Daniel H Palmer, PhD, Karen Morris, PhD, Marian Duggan, MSc, Prof David Cunningham, MD, D Alan Anthoney, MD, Pippa Corrie, MD, Srinivasan Madhusudan, MD, Prof Anthony Maraveyas, MD, Paul J Ross, MD, Justin S Waters, PhD, Prof Will P Steward, PhD, Charlotte Rees, MD, Sandy Beare, PhD, Prof Caroline Dive, PhD, John A Bridgewater, MD 
The Lancet Oncology 
Volume 16, Issue 8, Pages (August 2015)
DOI: /S (15)
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Kaplan-Meier curves for progression-free survival (A), and overall survival (B) by treatment
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Kaplan-Meier curves for overall survival, by number of circulating tumour cells in 7·5 mL whole blood, collected before treatment
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4
Kaplan-Meier curves for overall survival, by number of circulating VEGFR2 in the plasma, before treatment
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

6. Figure 5
Kaplan-Meier curves for overall survival, by concentrations of circulating PDGFbb in the plasma, before treatment
Plots show treatment effect by low (A) and high concentrations (B) of PDGFbb at baseline (median 162 pg/mL PDGFbb is the cutoff point), which show evidence of interaction between PDGFbb and treatment.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions